108 related articles for article (PubMed ID: 20098234)
1. Low-dose divalproex in agitated patients with Alzheimer's disease.
Dolder C; McKinsey J
J Psychiatr Pract; 2010 Jan; 16(1):63-7. PubMed ID: 20098234
[TBL] [Abstract][Full Text] [Related]
2. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
3. Agitated symptom response to divalproex following acute brain injury.
Chatham Showalter PE; Kimmel DN
J Neuropsychiatry Clin Neurosci; 2000; 12(3):395-7. PubMed ID: 10956575
[TBL] [Abstract][Full Text] [Related]
4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
5. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
Gleason RP; Schneider LS
J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457
[TBL] [Abstract][Full Text] [Related]
6. Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease.
Risse SC; Lampe TH; Cubberley L
J Clin Psychiatry; 1987 May; 48(5):207-8. PubMed ID: 2883174
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
8. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
[TBL] [Abstract][Full Text] [Related]
9. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics.
Lemke MR
J Clin Psychiatry; 1995 Aug; 56(8):354-7. PubMed ID: 7635851
[TBL] [Abstract][Full Text] [Related]
10. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid for agitation in dementia.
Lonergan ET; Cameron M; Luxenberg J
Cochrane Database Syst Rev; 2004; (2):CD003945. PubMed ID: 15106227
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled study of divalproex sodium for agitation in dementia.
Porsteinsson AP; Tariot PN; Erb R; Cox C; Smith E; Jakimovich L; Noviasky J; Kowalski N; Holt CJ; Irvine C
Am J Geriatr Psychiatry; 2001; 9(1):58-66. PubMed ID: 11156753
[TBL] [Abstract][Full Text] [Related]
13. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
14. Rapid oral loading of extended release divalproex in patients with acute mania.
Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D
Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
Martinez JM; Russell JM; Hirschfeld RM
Depress Anxiety; 1998; 7(2):83-6. PubMed ID: 9614597
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
17. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
Buckley PF; Paulsson B; Brecher M
J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: influence of drug-related morbidity on total cost of treatment.
Conney J; Kaston B
Am J Manag Care; 1999 Feb; 5(2):197-204. PubMed ID: 10346515
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of perospirone on aggressive behavior associated with dementia.
Sato S; Mizukami K; Moro K; Tanaka Y; Asada T
Psychiatry Clin Neurosci; 2006 Feb; 60(1):106-9. PubMed ID: 16472367
[TBL] [Abstract][Full Text] [Related]
20. A review of anticonvulsants in treating agitated demented elderly patients.
Grossman F
Pharmacotherapy; 1998; 18(3):600-6. PubMed ID: 9620110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
